Table 1.
Serum chemistry, body weight and changes in parathyroid features with treatment
| Vehicle (n = 7) | Erlotinib (n = 8) | 1,25D (n = 7) | Erlotinib + 1,25D (n = 6) | |
|---|---|---|---|---|
| ICa (mg/dL) | 4.56 ± 0.08 | 4.68 ± 0.12 | 4.71 ± 0.07 | 4.76 ± 0.14 |
| Creatinine (mg/dL) | 1.38 ± 0.12 | 1.20 ± 0.12 | 1.20 ± 0.08 | 1.14 ± 0.10 |
| Total Ca (mg/dL) | 9.95 ± 0.16 | 10.32 ± 0.20 | 10.6 ± 0.10 | 10.43 ± 0.23 |
| P (mg/dL) | 7.74 ± 0.63 | 8.06 ± 0.64 | 7.16 ± 0.48 | 7.66 ± 0.63 |
| PTH (pg/mL) | 427.6 ± 120.0 | 414.9 ± 116.0 | 359.6 ± 62.5 | 280.0 ± 82.2 |
| Body weight (g) | 271.0 ± 4.8 | 272.4 ± 3.7 | 277.1 ± 4.7 | 272.0 ± 5.4 |
| PCNA (+nuclei/area) | 0.42 ± 0.08 (N = 12) | 0.21 ± 0.03 (N = 14)* | 0.28 ± 0.07 (N = 9) | 0.14 ± 0.05 (N = 8)*** |
| CEBPβ (IOD/area) | 36.6 ± 5.3 | 37.7 ± 6.3 | 39.4 ± 5.5 | 56.6 ± 4.7* |
Values indicate the mean ± SEM in 5/6NX rats fed a high P (HP) diet and treated with vehicle, erlotinib (6 mg/kg bw, daily, i.p. in 100 μL DMSO), calcitriol (1,25D, 4 ng thrice weekly in 200 μL of propylene glycol–PBS 1:1) or the combination, from week 2 to week 4 after 5/6NX.
ICa, ionized calcium; PTH, parathyroid hormone; PCNA, proliferating cell nuclear antigen, where n is the number of rats and N is the number of PTGs examined.
*, **and ***indicate P < 0.05; P < 0.01 and P < 0.001 versus HP.